Page last updated: 2024-09-05

sb 203580 and vadimezan

sb 203580 has been researched along with vadimezan in 2 studies

Compound Research Comparison

Studies (sb 203580)	Trials (sb 203580)	Recent Studies (post-2010) (sb 203580)	Studies (vadimezan)	Trials (vadimezan)	Recent Studies (post-2010) (vadimezan)
3,489	4	1,137	272	16	101

Protein Interaction Comparison

Protein	Taxonomy	sb 203580 (IC50)	vadimezan (IC50)
Stimulator of interferon genes protein	Mus musculus (house mouse)		1.2

Research

Studies (2)

Timeframe	Studies, this research(%)	All Research%
pre-1990	0 (0.00)	18.7374
1990's	0 (0.00)	18.2507
2000's	1 (50.00)	29.6817
2010's	1 (50.00)	24.3611
2020's	0 (0.00)	2.80

Authors

Authors	Studies
Baguley, BC; Kelland, LR; Marshall, ES; Zhao, L	1
Albelda, SM; Cheng, G; Ching, LM; Fridlender, ZG; Sun, J; Wang, LC	1

Other Studies

2 other study(ies) available for sb 203580 and vadimezan

Article	Year
Evidence for the involvement of p38 MAP kinase in the action of the vascular disrupting agent 5,6-dimethylxanthenone-4-acetic acid (DMXAA). Investigational new drugs, 2007, Volume: 25, Issue:3 Topics: Angiogenesis Inhibitors; Angiogenic Proteins; Animals; Cell Line, Tumor; Cell Proliferation; Cell Shape; Collagen; Dose-Response Relationship, Drug; Drug Combinations; Gene Expression Profiling; Gene Expression Regulation, Neoplastic; Humans; Imidazoles; Laminin; MAP Kinase Signaling System; Melanoma; Mice; Mice, Nude; p38 Mitogen-Activated Protein Kinases; Protein Kinase Inhibitors; Proteoglycans; Pyridines; RNA, Messenger; Xanthones; Xenograft Model Antitumor Assays	2007
Activation of the nucleotide oligomerization domain signaling pathway by the non-bacterially derived xanthone drug 5'6-dimethylxanthenone-4-acetic acid (Vadimezan). The Journal of biological chemistry, 2010, Apr-02, Volume: 285, Issue:14 Topics: Antineoplastic Agents; Cells, Cultured; Chemokine CXCL10; Enzyme Inhibitors; Humans; Imidazoles; Immunoblotting; Kidney; Luciferases; Mesothelioma; NF-kappa B; Nod1 Signaling Adaptor Protein; Nod2 Signaling Adaptor Protein; Nucleotides; Pyridines; Receptor-Interacting Protein Serine-Threonine Kinase 2; Reverse Transcriptase Polymerase Chain Reaction; RNA, Messenger; RNA, Small Interfering; Signal Transduction; Xanthones	2010

Article

Year

Evidence for the involvement of p38 MAP kinase in the action of the vascular disrupting agent 5,6-dimethylxanthenone-4-acetic acid (DMXAA).

Investigational new drugs, 2007, Volume: 25, Issue:3

Topics: Angiogenesis Inhibitors; Angiogenic Proteins; Animals; Cell Line, Tumor; Cell Proliferation; Cell Shape; Collagen; Dose-Response Relationship, Drug; Drug Combinations; Gene Expression Profiling; Gene Expression Regulation, Neoplastic; Humans; Imidazoles; Laminin; MAP Kinase Signaling System; Melanoma; Mice; Mice, Nude; p38 Mitogen-Activated Protein Kinases; Protein Kinase Inhibitors; Proteoglycans; Pyridines; RNA, Messenger; Xanthones; Xenograft Model Antitumor Assays

2007

Activation of the nucleotide oligomerization domain signaling pathway by the non-bacterially derived xanthone drug 5'6-dimethylxanthenone-4-acetic acid (Vadimezan).

The Journal of biological chemistry, 2010, Apr-02, Volume: 285, Issue:14

Topics: Antineoplastic Agents; Cells, Cultured; Chemokine CXCL10; Enzyme Inhibitors; Humans; Imidazoles; Immunoblotting; Kidney; Luciferases; Mesothelioma; NF-kappa B; Nod1 Signaling Adaptor Protein; Nod2 Signaling Adaptor Protein; Nucleotides; Pyridines; Receptor-Interacting Protein Serine-Threonine Kinase 2; Reverse Transcriptase Polymerase Chain Reaction; RNA, Messenger; RNA, Small Interfering; Signal Transduction; Xanthones

2010